林可霉素生物合成的研究进展

林可霉素是林可链霉菌(Streptomyces lincolnensis)产生的林可酰胺类抗生素,它抑制细菌细胞的蛋白质合成,临床上主要用于治疗革兰氏阳性菌引起的感染性疾病。林可霉素生物合成基因簇已被克隆和测序。近年来,围绕林可酰胺和丙基脯氨酸的生物合成、调控等进行了深入研究,其硫化反应取得了突破性成果,本文综述了林可霉素生物合成的新进展。

Proceedings of lincomycin biosynthesis

Lincomycin, produced by Streptomyces lincolnensis, is a lincosamide antibiotic, which inhibits the protein biosynthesis of bacteria, and widely used to treat the infectious diseases caused by the Gram positive bacteria in clinic. Lincomycin biosynthetic gene cluster (lmb) was cloned and sequenced. Biosynthesis and regulation of lincosamide and propylproline were extensively elusive with the breakthrough of S-functionalization of lincomycin. This article reviewed the recent proceedings and achievements on the process of lincomycin biosynthesis.